In addition, the TBK1 antagonist resulted in the decreased level of α-SMA+ myofibroblasts in non-tumor liver tissues and IL-6 in tumor tissues demonstrated by IHC staining and ELISA (Supplementary Figure 5C, D). Here, TBK1 is linked to neoplasm.